Elsevier

Life Sciences

Volume 118, Issue 2, 24 November 2014, Pages 110-119
Life Sciences

Review article
Endothelin-1 and its role in the pathogenesis of infectious diseases

https://doi.org/10.1016/j.lfs.2014.04.021Get rights and content

Abstract

Endothelins are potent regulators of vascular tone, which also have mitogenic, apoptotic, and immunomodulatory properties (Rubanyi and Polokoff, 1994; Kedzierski and Yanagisawa, 2001; Bagnato et al., 2011). Three isoforms of endothelin have been identified to date, with endothelin-1 (ET-1) being the best studied. ET-1 is classically considered a potent vasoconstrictor. However, in addition to the effects of ET-1 on vascular smooth muscle cells, the peptide is increasingly recognized as a pro-inflammatory cytokine (Teder and Noble, 2000; Sessa et al., 1991). ET-1 causes platelet aggregation and plays a role in the increased expression of leukocyte adhesion molecules, the synthesis of inflammatory mediators contributing to vascular dysfunction. High levels of ET-1 are found in alveolar macrophages, leukocytes (Sessa et al., 1991) and fibroblasts (Gu et al., 1991). Clinical and experimental data indicate that ET-1 is involved in the pathogenesis of sepsis (Tschaikowsky et al., 2000; Goto et al., 2012), viral and bacterial pneumonia (Schuetz et al., 2008; Samransamruajkit et al., 2002), Rickettsia conorii infections (Davi et al., 1995), Chagas disease (Petkova et al., 2000, 2001), and severe malaria (Dai et al., 2012; Machado et al., 2006; Wenisch et al., 1996a; Dietmann et al., 2008). In this minireview, we will discuss the role of endothelin in the pathogenesis of infectious processes.

Graphical abstract

A schematic illustration of ET-1 effects on different cell types. Binding of ET-1 to its cognate receptors causes activation of monocytes, neutrophils, mast cells, and endothelial cells. ET-1 contributes to cytokine production, enhanced cellular adhesion molecule expression, as well as monocyte diapedesis. Additionally, ET receptor activation on vascular smooth muscle cells results in vasoconstriction, vascular permeability, and tissue remodeling.

  1. Download : Download high-res image (248KB)
  2. Download : Download full-size image

Introduction

Since its discovery, endothelin-1 (ET-1) has been shown to exhibit mitogenic properties and to regulate several physiologic functions, including salt and water homeostasis, vascular tone, and inflammation (Carpenter et al., 2005, Speciale et al., 1998, Chauhan et al., 2007). ET-1 is one of three known isoforms of endothelin, each encoded by a distinct peptide, but produced via a similar two-step metabolic pathway. Endothelins act through two seven transmembrane G-protein coupled receptors, endothelin receptor A (ETA) (Arai et al., 1990) and endothelin receptor B (ETB) (Sakurai et al., 1990, Masaki, 2004), to exert their effects on physiological and pathological processes. ET-1 is the most abundant isoform in vivo. It is formed by conversion of pre-pro-ET-1 into the intermediate precursor big ET-1, which is then cleaved by the ET converting enzyme (ECE) to form the active 21-amino acid peptide. ET-1 is synthesized by a variety of cells including endothelial cells, macrophages, cardiomyocytes, and neurons (Table 1) (Schinelli, 2002, Vignon-Zellweger et al., 2012, Kedzierski and Yanagisawa, 2001, van Harmelen et al., 2008, Dai et al., 2012, Nakagomi et al., 2000, Davis et al., 1992, De Souza et al., 2004, Kuddus et al., 2000, Jamal and Schneider, 2002, Ehrenreich et al., 1992, Matsushima et al., 2004, Giaid et al., 1989, D'Orleans-Juste et al., 2012, Yu et al., 1995).

ET-1 is constitutively synthesized and acts in an autocrine and paracrine manner in tissues throughout the body; its physiological plasma concentration is ~ 1 pM (Kedzierski and Yanagisawa, 2001). Binding of ET-1 to the ETA receptor triggers an increase in intracellular concentrations of calcium, resulting in very potent vasoconstriction and smooth muscle contraction (Chauhan et al., 2007, Ehrenreich et al., 1990). ET-1 can also promote vasodilation by inducing the production of NO via its interaction with the ETB receptor on endothelial cells (Chauhan et al., 2007, Tsukahara et al., 1994). Under normal physiological conditions ET-1 effects are controlled by these different mechanisms; however, abnormal activation of these cellular signaling pathways can play a role in the progression of disease.

Although typically regarded as a smooth muscle spasmogen, ET-1 has also been shown to participate in many inflammatory processes. While constitutively expressed throughout the body in healthy individuals, expression of ET-1 is increased with stress to the endothelium in response to cytokines, reactive oxygen species, angiotensin II, and thrombin (Kedzierski and Yanagisawa, 2001). High levels of ET-1 have been found in alveolar macrophages, leukocytes (Sessa et al., 1991) and fibroblasts (Gu et al., 1991), and it has been demonstrated that TNF-α facilitates the release of ET-1 by endothelial and epithelial cells (Sibson et al., 2002). In addition, there is ample evidence which suggests that ET-1 regulates leukocyte trafficking and cytokine production. Studies have shown that ET-1 stimulates monocyte production of IL-8 and MCP-1, known neutrophil and monocyte chemoattractants (Helset et al., 1994). Moreover, ET-1 can act as a mast cell activator, and lead to degranulation and release of inflammatory cytokines such as TNF-α and IL-6 (Matsushima et al., 2004). The mechanisms by which these cells enter targeted tissue are also under the control of the ET system. shRNA knockdown of different components of the ET system has demonstrated ET-1, ETB receptor, and ECE involvement in monocyte diapedesis (Reijerkerk et al., 2012). Cellular adhesion molecules like ICAM-1, VCAM-1, and e-selectin facilitate the leukocyte recruitment, binding, and infiltration. Human brain microvascular endothelial cells exposed to ET-1 upregulate the expression of ICAM-1, VCAM-1, and e-selectin (McCarron et al., 1993). This cascade of ET-1 mediated inflammatory events potentiates inflammation and the subsequent trafficking of immunocompetent cells into injured tissue.

Increased levels of ET-1 in response to stress have been implicated in a variety of infectious processes (Dietmann et al., 2008, Wanecek et al., 2000, Petkova et al., 2001, Koedel et al., 1997). Clinical and experimental data indicate that ET-1 is involved in the pathogenesis of sepsis (Arai et al., 1990, Wanecek et al., 2000, Andrade et al., 2012), viral and bacterial pneumonia (Schuetz et al., 2008, Samransamruajkit et al., 2002), Rickettsia conorii infections (Davi et al., 1995), Chagas disease (Bouallegue et al., 2007, Petkova et al., 2001), and severe malaria (Briyal et al., 2011, Dietmann et al., 2008, Wenisch et al., 1996, Brauner et al., 2000). ET-1 is associated with vasospasms, vascular damage, blood brain barrier (BBB) permeability, cardiovascular remodeling, and inflammation (Speciale et al., 1998, Chauhan et al., 2007, McCarron et al., 1993, Lin et al., 2004, Stanimirovic et al., 1994). Septic patients have increased ET-1 plasma concentrations, which correlate with renal dysfunction and disease severity (Piechota et al., 2007). Levels of cerebral spinal fluid (CSF) ET-1 are significantly elevated in individuals with bacterial meningitis, which is associated with abnormalities in cerebral blood flow (CBF) (Koedel et al., 1997). Additionally, ET-1 has been shown to play a major role in the development of vascular disruption caused by infection. In this review we will summarize the role of the ET in infectious diseases.

Section snippets

CNS Infections

The endothelin system is widely distributed throughout the central nervous system (CNS). Brain microvascular endothelial cells, neurons, and glial cells synthesize ET-1 and express receptors for the ligand (Schinelli, 2002, Dai et al., 2012). During pathological processes of the CNS, in addition to its vasoactive actions, upregulated ET-1 has been shown to cause an increase in BBB permeability, activate astrocytes, enhance cell adhesion molecule expression, as well as act as a neurotransmitter (

Endothelin and pneumonia

ET-1 is a potent vasoconstrictor and in the endothelium its synthesis is induced by hypoxia and pulmonary infection (Carpenter et al., 2005). In the infected lung ET-1 may be synthesized by a variety of cell types including bronchial epithelial, smooth muscle cells, endothelial cells, and inflammatory cells such as monocytes and macrophages.

Community-acquired pneumonia (CAP) is an important cause of morbidity and mortality world-wide and the precise microbial etiology of an episode of CAP is

Sepsis and endothelin

Despite the advances in our understanding of the mechanisms and therapeutic strategies in managing this disease complex, bacterial sepsis and septic shock continue to be important contributors to morbidity and death in the industrialized world, especially in the hospital setting, (Mayr et al., 2013). The administration of antibiotics within the early hours of the recognition with broad-spectrum antibiotics is a "goal" of therapy and is considered good medical practice. Nevertheless, even when

Chagas disease and endothelin

Chagas disease is a neglected tropical disease that is a life-long persistent infection. It is caused by the protozoan parasite, Trypanosoma cruzi, and is a major cause of morbidity and mortality in endemic areas of Latin America stretching from the Texas–Mexican border to almost the tip of the South American continent. Due to increased immigration to the non-endemic areas of North America, Europe, Asia and Australia this disease can no longer be considered an esoteric disease or a medical

Conclusions

The role of endothelins in the pathogenesis of infectious diseases has been an important field of study almost immediately since the discovery of the peptide. Though ET-1 is implicated in the pathogenesis of several processes with infectious diseases, there is no unifying hypothesis as to how ET-1 effects its actions, rendering the precise elucidation of this role difficult; particularly since the signaling pathways involved are complex, interrelated and redundant. Several of these disease

Conflict of interest statement

None

Acknowledgements

Supported by United States National Institutes of Health Grants NS069577 (MSD), AI076248 (HBT), T32AI 070117 (BDF); Burroughs-Wellcome Fund Career Award for Medical Scientists (MSD), Conselho Nacional do Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil; and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Belo Horizonte, Brazil (FSM).

References (180)

  • T. Filipovich et al.

    Regulation of glial inflammatory mediators synthesis: Possible role of endothelins

    Peptides

    (2008)
  • J. Gu et al.

    The biosynthesis of endothelin-like immunoreactivity in epithelium and fibroblasts of the human umbilical cord

    Tissue Cell

    (1991)
  • M.A. Iniguez et al.

    An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes

    J Biol Chem

    (2000)
  • A.B. Iskit et al.

    A new therapeutic approach for the treatment of sepsis

    Med Hypotheses

    (2004)
  • A.B. Iskit et al.

    Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock

    Eur J Pharmacol

    (2004)
  • K.S. Kim

    Acute bacterial meningitis in infants and children

    Lancet Infect Dis

    (2010)
  • R.H. Kuddus et al.

    Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes–an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis

    J Hepatol

    (2000)
  • J.J. Li et al.

    Endothelins-1/3 and endothelin-A/B receptors expressing glial cells with special reference to activated microglia in experimentally induced cerebral ischemia in the adult rats

    Neuroscience

    (2010)
  • F.S. Machado et al.

    Bioactive lipids in Trypanosoma cruzi infection

    Adv Parasitol

    (2011)
  • T. Masaki

    Historical review: Endothelin

    Trends Pharmacol Sci

    (2004)
  • H.I. Abdullah et al.

    NFAT regulates calcium-sensing receptor-mediated TNF production

    Am J Physiol Renal Physiol

    (2006)
  • C.L. Achim et al.

    Masliah E and Neurobehavioral Research Center Increased accumulation of intraneuronal amyloid beta in HIV-infected patients

    J Neuroimmune Pharmacol

    (2009)
  • S.S. Anand et al.

    The specific, reversible JNK inhibitor SP600125 improves survivability and attenuates neuronal cell death in experimental cerebral malaria (ECM)

    Parasitol Res

    (2013)
  • B.M. Ances et al.

    Dementia and neurocognitive disorders due to HIV-1 infection

    Semin Neurol

    (2007)
  • D. Andrade et al.

    Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: A converging pathway leading to chagasic vasculopathy

    Br J Pharmacol

    (2012)
  • H. Arai et al.

    Cloning and expression of a cDNA encoding an endothelin receptor

    Nature

    (1990)
  • A.W. Ashton et al.

    Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection

    J Exp Med

    (2007)
  • A. Bagnato et al.

    Role of the endothelin axis and its antagonists in the treatment of cancer

    Br J Pharmacol

    (2011)
  • F.G. Baptista et al.

    Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice

    Infect Immun

    (2010)
  • C. Bern et al.

    An estimate of the burden of Chagas disease in the United States

    Clin Infect Dis

    (2009)
  • A. Bouallegue et al.

    Endothelin-1-induced signaling pathways in vascular smooth muscle cells

    Curr Vasc Pharmacol

    (2007)
  • J.S. Brauner et al.

    Circulating endothelin-1 and tumor necrosis factor-α: Early predictors of mortality in patients with septic shock

    Intensive Care Med

    (2000)
  • S. Briyal et al.

    Endothelin-A Receptor Antagonists Prevent Amyloid-β-Induced Increase in ETA Receptor Expression, Oxidative Stress, and Cognitive Impairment

    J Alzheimers Dis

    (2011)
  • P.K. Busk et al.

    Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro

    Cardiovasc Res

    (2002)
  • T.C. Carpenter et al.

    Endothelin-mediated increases in lung VEGF content promote vascular leak in young rats exposed to viral infection and hypoxia

    Am J Physiol Lung Cell Mol Physiol

    (2005)
  • B. Chandrasekar et al.

    Temporal expression of pro-inflammatory cytokines and inducible nitric oxide synthase in experimental acute Chagasic cardiomyopathy

    Am J Pathol

    (1998)
  • A. Chauhan et al.

    Molecular programming of endothelin-1 in HIV-infected brain: Role of Tat in up-regulation of ET-1 and its inhibition by statins

    FASEB J

    (2007)
  • M. Christ-Crain et al.

    Biomarkers in the management of pneumonia

    Expert Rev Respir Med

    (2008)
  • R.S. Corral et al.

    Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes

    PLoS Negl Trop Dis

    (2013)
  • N.P. Curzen et al.

    Endothelin-1-induced contraction of pulmonary arteries from endotoxemic rats is attenuated by the endothelin-A receptor antagonist, BQ123

    Crit Care Med

    (1996)
  • G. Davi et al.

    Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever

    Thromb Haemost

    (1995)
  • L.E. Davis et al.

    Early viral brain invasion in iatrogenic human immunodeficiency virus infection

    Neurology

    (1992)
  • A.P. De Souza et al.

    Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection

    Parasitol Res

    (2004)
  • J.B. de Souza et al.

    Cerebral malaria: Why experimental murine models are required to understand the pathogenesis of disease

    Parasitology

    (2010)
  • M.S. Desruisseaux et al.

    Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA

    J Infect Dis

    (2008)
  • M. D'Haeseleer et al.

    Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1

    Proc Natl Acad Sci U S A

    (2013)
  • N. Didier et al.

    HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier

    Neuroreport

    (2002)
  • A. Dietmann et al.

    Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria

    Malar J

    (2008)
  • P. D'Orleans-Juste et al.

    Endothelin and bradykinin: 'Brothers-in-arms' in Chagas vasculopathies?

    Br J Pharmacol

    (2012)
  • H. Ehrenreich et al.

    Endothelins, peptides with potent vasoactive properties, are produced by human macrophages

    J Exp Med

    (1990)
  • Cited by (73)

    • Role of FAK signaling in chagasic cardiac hypertrophy

      2020, Brazilian Journal of Infectious Diseases
    • Lignans from Schisandra chinensis ameliorate alcohol and CCl<inf>4</inf>-induced long-term liver injury and reduce hepatocellular degeneration via blocking ETBR

      2020, Journal of Ethnopharmacology
      Citation Excerpt :

      The activation of HSCs can be mediated by multi-cytokines, such as TNF-α, TGF-β1, ROS, and endothelin-1 (ET-1), typically ET-1, which has been shown to contribute to pathological processes responsible for some liver diseases (Stewart et al., 2014). Endothelin (ET), a vasoconstrictor with high potency, can be secreted by vascular endothelial cells, vascular smooth muscle cells, bronchial epithelial cells, alveolar macrophages, HSCs, hepatic sinusoidal endothelial cells, and fibroblasts in the human body (Freeman el al., 2014; Kopriva et al., 2006). To date, three kinds of ETs (ET-1, ET-2, and ET-3) have been discovered, among which ET-1 is closely associated with the development of many diseases (Horinouchi et al., 2013; Stewart et al., 2014).

    • Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?

      2020, Nutrition
      Citation Excerpt :

      Treatment with vitamin C decreases IL-6 and blocks in vivo the release of IL-6 in the endothelium induced by endothelin-1 (ET-1) in humans [23,38]. ET-1 is a potent vasoconstrictor peptide, but also recognized as a proinflammatory cytokine, including in the lungs, and its increased expression has been associated with pneumonia, pulmonary hypertension, interstitial lung fibrosis, and acute respiratory distress syndrome [39–41]. In patients with severe COVID-19 who survive, cytokine levels, including IL-6, gradually return later in the course of the disease to levels comparable with those in mild cases [33].

    View all citing articles on Scopus
    View full text